NovoCure LtdNVCREarnings & Financial Report
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
NVCR Q1 FY2026 Key Financial Metrics
Revenue
$174.1M
Gross Profit
$135.1M
Operating Profit
N/A
Net Profit
$-71.1M
Gross Margin
77.6%
Operating Margin
N/A
Net Margin
-40.9%
YoY Growth
12.3%
NovoCure Ltd Q1 FY2026 Financial Summary
NovoCure Ltd reported revenue of $174.1M (up 12.3% YoY) for Q1 FY2026, with a net profit of $-71.1M (down 107.3% YoY) (-40.9% margin). Cost of goods sold was $38.9M.
Key Financial Metrics
| Total Revenue | $174.1M |
|---|---|
| Net Profit | $-71.1M |
| Gross Margin | 77.6% |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
NovoCure Ltd Annual Revenue by Year
NovoCure Ltd annual revenue history includes year-by-year totals (for example, 2025 revenue was $655.4M).
NovoCure Ltd Quarterly Revenue & Net Profit History
NovoCure Ltd results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $174.1M | +12.3% | $-71.1M | -40.9% |
| Q4 FY2025 | $174.3M | +8.1% | $-24.5M | -14.1% |
| Q3 FY2025 | $167.2M | +7.8% | $-37.3M | -22.3% |
| Q2 FY2025 | $158.8M | +5.6% | $-40.1M | -25.3% |
| Q1 FY2025 | $155.0M | +11.9% | $-34.3M | -22.1% |
| Q4 FY2024 | $161.3M | +20.5% | $-65.9M | -40.9% |
| Q3 FY2024 | $155.1M | +21.8% | $-30.6M | -19.7% |
| Q2 FY2024 | $150.4M | +19.3% | $-33.4M | -22.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150.4M | $155.1M | $161.3M | $155.0M | $158.8M | $167.2M | $174.3M | $174.1M |
| YoY Growth | 19.3% | 21.8% | 20.5% | 11.9% | 5.6% | 7.8% | 8.1% | 12.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.21B | $1.22B | $1.24B | $1.25B | $1.25B | $1.36B | $804.3M | $787.9M |
| Liabilities | $850.4M | $861.2M | $880.6M | $886.9M | $896.4M | $1.02B | $463.9M | $457.2M |
| Equity | $361.8M | $360.8M | $360.2M | $362.0M | $349.4M | $341.3M | $340.5M | $330.7M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.7M | $10.4M | $-3.5M | $-35.7M | $-15.9M | $20.6M | $-18.0M |